NanoViricides, Inc. — Form 10-Q Summary
Reporting period: Three months ended September 30, 2021, the company’s first fiscal quarter of FY2022; comparable period ended September 30, 2020. The filing is dated November 15, 2021.
Business context
NanoViricides is a pre-revenue antiviral drug-development company. Its lead programs are COVID-19 candidates NV-CoV-2 and NV-CoV-2-R; the company also describes a shingles candidate and other early-stage antiviral programs. It reports no commercialized products or revenue. Research and development activities rely on the company’s facilities and on external collaborators, CROs, and related-party licensor TheraCour Pharma.
Key financial metrics
| Metric | Quarter ended September 30, 2021 | Comparable 2020 period / prior balance |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $2.097 million | $1.573 million |
| General and administrative expense | $515,445 | $697,312 |
| Total operating expenses / operating loss | $2.612 million | $2.270 million |
| Net loss | $2.613 million; $0.23 per share | $2.311 million; $0.22 per share |
| Operating cash flow | $(724,231) | $(2.236) million |
| Cash and cash equivalents | $19.697 million | $20.517 million at June 30, 2021 |
| Current assets | $19.892 million | $20.824 million at June 30, 2021 |
| Current liabilities | $869,467 | $351,146 at June 30, 2021 |
| Total stockholders’ equity | $28.309 million | $29.911 million at June 30, 2021 |
There is no product revenue, so operating and net profit margins are not meaningful. The company reported $8.935 million of net property and equipment on its balance sheet and no long-term debt. Cash declined by $819,883 during the quarter; investing outflow was $24,313 and financing outflow was $71,339. The prior-year quarter included $10.442 million of net equity-financing proceeds.
Material changes and unusual items
- R&D expense increased $523,849 year over year, principally reflecting a $935,088 noncash preferred-stock license milestone to TheraCour under a new COVID-19 license, partly offset by lower outside-laboratory expenses.
- Net loss increased $301,835 year over year. Lower G&A and interest expense partly offset the higher R&D expense.
- Accounts payable to related parties rose substantially; reported related-party accounts payable was $705,177 in current liabilities. The note describes a larger TheraCour payable, net of a two-month advance, and says $200,000 is deferred until an IND filing.
- During the quarter, the company issued 100,000 Series A preferred shares for the COVID-19 license, along with preferred shares for compensation and common shares for services and director fees. Common shares outstanding were 11,525,203 at September 30, up from 11,515,170 at June 30.
Outlook, commentary, and risks
- Management said existing resources were expected to fund planned operations through at least the next 12 months; Note 2 more specifically estimates funding through November 2022. Management also said additional capital will be needed for longer-term operations, clinical development, and other pipeline programs. Funding needs and timing may change, and future financing is not assured.
- The company was preparing regulatory submissions and clinical-trial protocols for NV-CoV-2 and NV-CoV-2-R. It reported completion of preclinical safety work and receipt of CRO reports, but provided no clear timeline for IND submission or clinical-trial commencement. Trial-site capacity, regulatory review, and reliance on external parties create timing uncertainty.
- Management described preclinical efficacy and safety results as encouraging; these are company-reported preclinical findings, not evidence of human clinical efficacy or regulatory approval.
- COVID-19 disrupted the company’s prior shingles-trial plans and may complicate patient recruitment. Management also cited potential market disruption, supply-chain issues, and adverse effects on future fundraising.
- The company remains dependent on TheraCour for licensed technology and development services. The COVID-19 license includes milestone payments and a 15% royalty on defined net sales if products are commercialized.
- Disclosure controls and procedures were concluded to be ineffective at September 30, 2021 because of an unremediated material weakness involving period-end review and insufficient personnel and resources. Management described a remediation committee.
- No pending or threatened legal proceedings were reported to the company’s knowledge. No off-balance-sheet arrangements were reported for the quarter.
Important facts for investors to verify
- Confirm the fiscal-period label: the filing covers the quarter ended September 30, 2021, not calendar Q1 2021.
- Track whether and when an IND is filed and accepted, and whether clinical trials begin; the filing gives no firm timeline.
- Assess cash runway against planned clinical-trial spending, future financing requirements, and the remaining capacity of the ATM offering.
- Review the related-party license terms, payable balance, milestone obligations, and 15% commercialization royalty.
- Reconcile net property and equipment: the balance sheet reports $8.935 million, while one MD&A passage reports $8.395 million, an apparent inconsistency in the filing text.
- Monitor remediation of the material weakness and whether disclosure controls are subsequently found effective.